NO981454D0 - Anti-FAS-antistoffer - Google Patents

Anti-FAS-antistoffer

Info

Publication number
NO981454D0
NO981454D0 NO981454A NO981454A NO981454D0 NO 981454 D0 NO981454 D0 NO 981454D0 NO 981454 A NO981454 A NO 981454A NO 981454 A NO981454 A NO 981454A NO 981454 D0 NO981454 D0 NO 981454D0
Authority
NO
Norway
Prior art keywords
fas
fas antibodies
antibodies
human
abnormalities
Prior art date
Application number
NO981454A
Other languages
English (en)
Other versions
NO981454L (no
Inventor
Nobufusa Serizawa
Kimihisa Ichikawa
Jun Ohsumi
Masahiko Ohtsuki
Hideyuki Haruyama
Tohru Takahashi
Hiroko Yoshida
Akio Shiraishi
Shin Yonehara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO981454D0 publication Critical patent/NO981454D0/no
Publication of NO981454L publication Critical patent/NO981454L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO981454A 1997-04-01 1998-03-31 Anti-FAS-antistoffer NO981454L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8295397 1997-04-01
JP16908897 1997-06-25
JP27606497 1997-10-08

Publications (2)

Publication Number Publication Date
NO981454D0 true NO981454D0 (no) 1998-03-31
NO981454L NO981454L (no) 1998-10-02

Family

ID=27304060

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981454A NO981454L (no) 1997-04-01 1998-03-31 Anti-FAS-antistoffer

Country Status (17)

Country Link
EP (1) EP0909816A1 (no)
KR (1) KR19980080993A (no)
CN (1) CN1207395A (no)
AR (1) AR010139A1 (no)
AU (1) AU734758B2 (no)
BR (1) BR9803296A (no)
CA (1) CA2233783A1 (no)
CZ (1) CZ294340B6 (no)
HU (1) HUP9800744A3 (no)
ID (1) ID20117A (no)
IL (1) IL123888A0 (no)
NO (1) NO981454L (no)
NZ (1) NZ330095A (no)
PL (1) PL325667A1 (no)
RU (1) RU2212412C2 (no)
TR (1) TR199800604A3 (no)
TW (1) TW526205B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
WO1999037682A2 (en) * 1998-01-23 1999-07-29 F.Hoffmann-La Roche Ag Antibodies against human il-12
ATE391136T1 (de) 1998-06-18 2008-04-15 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
CN1191861C (zh) 1999-05-24 2005-03-09 三共株式会社 含有抗Fas抗体的药物组合物
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2003022299A1 (en) * 2001-08-01 2003-03-20 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
ES2732276T3 (es) 2001-08-23 2019-11-21 Rsr Ltd Regiones del epítopo de un receptor de tirotropina (TSH), usos del mismo y anticuerpos para el mismo
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
CN102170905B (zh) * 2008-08-01 2016-08-03 阿克西斯股份有限公司 骨关节炎治疗剂及预防剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
EP0739350B1 (en) * 1994-01-07 2008-02-27 Mochida Pharmaceutical Co., Ltd. Ligand that binds fas antigen
WO1996040041A2 (en) * 1995-06-07 1996-12-19 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
TW526205B (en) 2003-04-01
TR199800604A2 (xx) 1999-10-21
NZ330095A (en) 1998-12-23
AU5970198A (en) 1998-10-08
AR010139A1 (es) 2000-05-17
CN1207395A (zh) 1999-02-10
NO981454L (no) 1998-10-02
TR199800604A3 (tr) 1999-10-21
PL325667A1 (en) 1998-10-12
RU2212412C2 (ru) 2003-09-20
CA2233783A1 (en) 1998-10-01
HUP9800744A3 (en) 2001-04-28
EP0909816A1 (en) 1999-04-21
HUP9800744A2 (hu) 1999-02-01
ID20117A (id) 1998-10-01
BR9803296A (pt) 2000-01-11
IL123888A0 (en) 1998-10-30
KR19980080993A (ko) 1998-11-25
CZ98598A3 (cs) 1998-10-14
AU734758B2 (en) 2001-06-21
HU9800744D0 (en) 1998-05-28
CZ294340B6 (cs) 2004-12-15

Similar Documents

Publication Publication Date Title
NO994750D0 (no) Anti-Fas-antistoffer
ES2124209T3 (es) Anticuerpos monoclonales mejorados reactivos con caquectina.
NO20001104L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende slike samt terapeutiske anvendelser derav
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
DE60005953D1 (de) Stapelbare statische mischelemente
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE60042648D1 (de) Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
NO20002957L (no) Behandling med anti-ErbB2-antistoffer
GR3026219T3 (en) Mouse monoclonal antibodies
DE69605187D1 (de) Gurtbefestiger mit voreingestellten klammern
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
ATE286510T1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
NO981454D0 (no) Anti-FAS-antistoffer
DE3703711A1 (de) Kreuz-schuetzende monoklonale humanantikoerper und diese enthaltende mittel
DE60045681D1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
FR2631239B1 (fr) Anticorps monoclonal humain et hybridome le produisant
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
FR2773157B1 (fr) Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide
KR950702207A (ko) Tlp 복합체에 대한 항원성 부위와 이의 항체(antigenic regions of tumour-liberated particles (tlp) complexes and antibodies against them)
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
IT1233005B (it) Anticorpo umano monoclonale, composizione terapeutica che lo contiene linea cellulare capace di produrre l'anticorpo, procedimento per la sua produzione
TR199902410A2 (xx) Anti-Fas Antikorları
DK0741746T3 (da) Thymosin alpha 1-analoger
BR7002742U (pt) Calcinhas e cuecas com ou sem absorventes descartaveis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application